HIF-1: An oxygen and metal responsive transcription factor

Cancer Biology and Therapy

Volumn 3, Issue 1, 2004, Pages 29-35

  Maxwell, Patrick ^a   Salnikow, Konstantin ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cobalt; HIF 1 transcription factor; Hypoxia; Nickel; VHL

Indexed keywords

COBALT; ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR 1; METAL; NICKEL; OXYGEN; OXYGENASE; PROTEIN P53; CARCINOGEN; DNA BINDING PROTEIN; ENZYME; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR;

ANGIOGENESIS; CANCER; CANCER GROWTH; CARCINOGENESIS; ENZYME ACTIVITY; GENE EXPRESSION; GENE TARGETING; GENETIC REGULATION; HUMAN; HYPOTHESIS; HYPOXIA; MOLECULAR MECHANICS; NONHUMAN; OXYGEN CONSUMPTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; TRANSCRIPTION REGULATION; TUMOR GROWTH; ANIMAL; CELL HYPOXIA; CELL TRANSFORMATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY;

ANIMALS; CARCINOGENS; CELL HYPOXIA; CELL TRANSFORMATION, NEOPLASTIC; COBALT; DNA-BINDING PROTEINS; ENZYMES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASMS; NICKEL; NUCLEAR PROTEINS; OXYGEN CONSUMPTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 3142523739     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.1.547     Document Type: Review

References (101)

1. CR H. CRC Handbook of Chemistry and Physics. CRC Press, 1913-95.
2. Pihlajaniemi T, Myllyla R, Kivirikko KI. Prolyl 4-hydroxylase and its role in collagen synthesis. J Hepatol 1991; 13:S2-7.
3. 2 sensing. Science 2001; 292:464-8.
4. 2-regulated prolyl hydroxylation. Science 2001; 292:468-72.
5. Hayaishi O, Nozaki M. Nature and mechanisms of oxygenases. Science 1969; 164:389-96.
6. Ortiz de Montellano PR, De Voss JJ. Oxidizing species in the mechanism of cytochrome P450. Nat Prod Rep 2002; 19:477-93.
7. Sundaramoorthy M, Terner J, Poulos TL. The crystal structure of chloroperoxidase: A heme peroxidase - cytochrome P450 functional hybrid. Structure 1995; 3:1367-77.
8. Groves JT, Wang CC. Nitric oxide synthase: Models and mechanisms. Curr Opin Chem Biol 2000; 4:687-95.
9. Sono M, Roach MP, Coulter ED, Dawson JH. Heme-Containing Oxygenases. Chem Rev 1996; 96:2841-88.
10. Ryle MJ, Hausinger RP. Nonheme iron oxygenases. Curr Opin Chem Biol 2002; 6:193-201.
11. Solomon EI, Decker A, Lehnert N. Nonheme iron enzymes: Contrasts to heme catalysis. Proc Natl Acad Sci USA 2003; 100:3589-94.
12. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 2002; 16:1466-71.
13. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399:271-5.
14. Hewitson KS, McNeill LA, Elkins JM, Schofield CJ. The role of iron and 2-oxoglutarate oxygenases in signalling. Biochem Soc Trans 2003; 31:510-5.
15. Rohde J-U, In J-H, Lim MH, Brennessel WW, Bukowski MR, Stubna A, et al. Crystallographic and Spectroscopic Characterization of a Nonheme Fe(IV)&cjs0811;O Complex. Science 2003; 299:1037-9.
16. Ivan M, Haberberger T, Gervasi DC, Michelson KS, Gunzler V, Kondo K, et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci USA 2002; 99:13459-64.
17. Hirsila M, Koivunen P, Gunzler V, Kivirikko KI, Myllyharju J. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem 2003; 278:30772-80.
18. Hewitson KS, McNeill LA, Riordan MV, Tian YM, Bullock AN, Welford RW, et al. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem 2002; 277:26351-5.
19. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 1993; 90:4304-8.
20. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995; 270:1230-7.
21. Arany Z, Huang LE, Eckner R, Bhattacharya S, Jiang C, Goldberg MA, et al. An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci USA 1996; 93:12969-73.
22. Jiang BH, Semenza GL, Bauer C, Marti HH. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol 1996; 271:C1172-80.
23. Wiesener MS, Turley H, Allen WE, Willam C, Eckardt KU, Talks KL, et al. Induction of endothelial PAS domain protein-1 by hypoxia: Characterization and comparison with hypoxia-inducible factor-1alpha. Blood 1998; 92:2260-8.
24. Tian H, Hammer RE, Matsumoto AM, Russell DW, McKnight SL. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev 1998; 12:3320-4.
25. Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 1998; 12:149-62.
26. Hon WC, Wilson MI, Harlos K, Claridge TD, Schofield CJ, Pugh CW, et al. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature 2002; 417:975-8.
27. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. Embo J 2001; 20:5197-206.
28. Min JH, Yang H, Ivan M, Gertler F, Kaelin Jr WG,. Pavletich NP. Structure of an HIF-1alpha -pVHL complex: Hydroxyproline recognition in signaling. Science 2002; 296:1886-9.
29. McNeill LA, Hewitson KS, Claridge TD, Seibel JF, Horsfall LE, Schofield CJ. Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the beta-carbon of asparagine-803. Biochem J 2002; 367:571-5.
30. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001; 107:43-54.
31. Mahon PC, Hirota K, Semenza GL. FIH-1: A novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 2001; 15:2675-86.
32. Taylor MS. Characterization and comparative analysis of the EGLN gene family. Gene 2001; 275:125-32.
33. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001; 294:1337-40.
34. Hanson ES, Rawlins ML, Leibold EA. Oxygen and iron regulation of iron regulatory protein 2. J Biol Chem 2003; 278:40337-42.
35. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. Embo J 2003; 22:4082-90.
36. Semenza GL. Regulation of erythropoietin production. New insights into molecular mechanisms of oxygen homeostasis. Hematol Oncol Clin North Am 1994; 8:863-84.
37. Maxwell PH, Pugh CW, Ratcliffe PJ. Inducible operation of the erythropoietin 3′ enhancer in multiple cell lines: Evidence for a widespread oxygen sensing mechanism. Proc Natl Acad Sci USA 1993; 90:2423-7.
38. Maxwell PH, Ratcliffe PJ. The erythropoietin-producing cells. Exp Nephrol 1996; 4:309-13.
39. Adamson JW. Regulation of red blood cell production. Am J Med 1996; 101:4S-6S.
40. Maxwell PH, Pugh CW, Ratcliffe PJ. Activation of the HIF pathway in cancer. Curr Opin Genet Dev 2001; 11:293-9.
41. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721-32.
42. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997; 94:8104-9.
43. Chen J, Zhao S, Nakada K, Kuge Y, Tamaki N, Okada F, et al. Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am J Pathol 2003; 162:1283-91.
44. Kaelin Jr WG, Maher ER. The VHL tumour-suppressor gene paradigm. Trends Genet 1998; 14:423-6.
45. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin Jr WG. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002; 1:237-46.
46. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 2002; 1:247-55.
47. Brahmachari HD, Joseph S. Cobalt compounds for the control of hypoxic stress. Aerosp Med 1973; 44:636-8.
48. Salnikow K, Blagosklonny MV, Ryan H, Johnson R, Costa M. Carcinogenic nickel induces genes involved with hypoxic stress. Cancer Res 2000; 60:38-41.
49. Salnikow K, An WG, Melillo G, Blagosklonny MV, Costa M. Nickel-induced transformation shifts the balance between HIF-1 and p53 transcription factors. Carcinogenesis 1999; 20:1819-23.
50. Morse EE, Lee TY, Reiss RF, Sunderman Jr FW. Dose-response and time-response study of erythrocytosis in rats after intrarenal injection of nickel subsulfide. Ann Clin Lab Sci 1977; 7:17-24.
51. Jasmin G, Solymoss B. Polycythemia induced in rats by intrarenal injection of nickel sulfide Ni3S2. Proc Soc Exp Biol Med 1975; 148:774-6.
52. Goldberg MA, Dunning SP, Bunn HF. Regulation of the erythropoietin gene: Evidence that the oxygen sensor is a heme protein. Science 1988; 242:1412-5.
53. Namiki A, Brogi E, Kearney M, Kim EA, Wu T, Couffinhal T, et al. Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J Biol Chem 1995; 270:31189-95.
54. Oskarsson A, Reid MC, Sunderman Jr FW. Effects of cobalt chloride, nickel chloride, and nickel subsulfide upon erythropoiesis in rats. Ann Clin Lab Sci 1981; 11:165-72.
55. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992; 12:5447-54.
56. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: Implications for models of hypoxia signal transduction. Blood 1993; 82:3610-5.
57. Salnikow K, Davidson T, Zhang Q, Chen LC, Su W, Costa M. The involvement of hypoxia-inducible transcription factor-1-dependent pathway in nickel carcinogenesis. Cancer Res 2003; 63:3524-30.
58. Salnikow K, Davidson T, Kluz T, Chen H, Zhou D, Costa M. GeneChip analysis of signaling pathways effected by nickel. J Environ Monit 2003; 5:206-9.
59. Batie CJ, Ballou DP. Phthalate dioxygenase. Methods Enzymol 1990; 188:61-70.
60. Batie CJ, LaHaie E, Ballou DP. Purification and characterization of phthalate oxygenase and phthalate oxygenase reductase from Pseudomonas cepacia. J Biol Chem 1987; 262:1510-8.
61. Gunshin H, Mackenzie B, Berger UV, Gunshin Y, Romero MF, Boron WF, et al. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 1997; 388:482-8.
62. Williams DR. Metals, ligands, and cancer. Chem Rev 1972; 72:203-13.
63. Smith MW, Shenoy KB, Debnam ES, Dashwood MR, Churchill LJ, Srai SK. Divalent metal inhibition of nonhaem iron uptake across the rat duodenal brush border membrane. Br J Nutr 2002; 88:51-6.
64. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: Implications for models of hypoxia signal transduction. Blood 1993; 82:3610-5.
65. Yuan Y, Beitner-Johnson D, Millhorn DE. Hypoxia-inducible factor 2alpha binds to cobalt in vitro. Biochem Biophys Res Commun 2001; 288:849-54.
66. Yuan Y, Hilliard G, Ferguson T, Millhorn DE. Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. J Biol Chem 2003; 278:15911-6.
67. Salnikow K, Su W, Blagosklonny MV, Costa M. Carcinogenic metals induce hypoxia-inducible factor-stimulated transcription by reactive oxygen species-independent mechanism. Cancer Res 2000; 60:3375-8.
68. Report of the International Committee on Nickel Carcinogenesis in Man. Scand J Work Environ Health 1990; 16:1-82.
69. Kasprzak KS, Sunderman FW, Salnikow K. Nickel carcinogenesis. Mutat Res 2003; 533:67-97.
70. Doll R, Morgan LG, Speizer FE. Cancers of the lung and nasal sinuses in nickel workers. Br J Cancer 1970; 24:623-32.
71. Roberts RS, Julian JA, Muir DC, Shannon HS. A study of mortality in workers engaged in the mining, smelting, and refining of nickel. II: Mortality from cancer of the respiratory tract and kidney. Toxicol Ind Health 1989; 5:975-93.
72. Enterline PE, Marsh GM. Mortality among workers in a nickel refinery and alloy manufacturing plant in West Virginia. J Natl Cancer Inst 1982; 68:925-33.
73. Sunderman Jr FW. Carcinogenicity of nickel compounds in animals. IARC Sci Publ 1984; 127-42.
74. Denkhaus E, Salnikow K. Nickel essentiality, toxicity, and carcinogenicity. Crit Rev Oncol Hematol 2002; 42:35-56.
75. Sunderman Jr FW, Maenza RM, Hopfer SM, Mitchell JM, Allpass PR, Damjanov I. Induction of renal cancers in rats by intrarenal injection of nickel subsulfide. J Environ Pathol Toxicol 1979; 2:1511-27.
76. Sunderman Jr FW, Maenza RM. Comparisons of carcinogenicities of nickel compounds in rats. Res Commun Chem Pathol Pharmacol 1976; 14:319-30.
77. Biedermann KA, Landolph JR. Induction of anchorage independence in human diploid foreskin fibroblasts by carcinogenic metal salts. Cancer Res 1987; 47:3815-23.
78. Patierno SR, Dirscherl LA, Xu J. Transformation of rat tracheal epithelial cells to immortal growth variants by particulate and soluble nickel compounds. Mutat Res 1993; 300:179-93.
79. Trott DA, Cuthbert AP, Overell RW, Russo I, Newbold RF. Mechanisms involved in the immortalization of mammalian cells by ionizing radiation and chemical carcinogens. Carcinogenesis 1995; 16:193-204.
80. Cobalt and cobalt compounds. IARC Monogr Eval Carcinog Risks Hum 1991; 52:363-472.
81. Lison D, De Boeck M, Verougstraete V, Kirsch-Volders M. Update on the genotoxicity and carcinogenicity of cobalt compounds. Occup Environ Med 2001; 58:619-25.
82. Fletcher GG, Rossetto FE, Turnbull JD, Nieboer E. Toxicity, uptake, and mutagenicity of particulate and soluble nickel compounds. Environ Health Perspect 1994; 102 Suppl 3:69-79.
83. Biggart NW, Costa M. Assessment of the uptake and mutagenicity of nickel chloride in salmonella tester strains. Mutat Res 1986; 175:209-15.
84. Kargacin B, Klein CB, Costa M. Mutagenic responses of nickel oxides and nickel sulfides in Chinese hamster V79 cell lines at the xanthine-guanine phosphoribosyl transferase locus. Mutat Res 1993; 300:63-72.
85. Lee YW, Klein CB, Kargacin B, Salnikow K, Kitahara J, Dowjat K, et al. Carcinogenic nickel silences gene expression by chromatin condensation and DNA methylation: A new model for epigenetic carcinogens. Mol Cell Biol 1995; 15:2547-57.
86. Broday L, Peng W, Kuo MH, Salnikow K, Zoroddu M, Costa M. Nickel compounds are novel inhibitors of histone H4 acetylation. Cancer Res 2000; 60:238-41.
87. Salnikow K, Cosentino S, Klein C, Costa M. Loss of thrombospondin transcriptional activity in nickel-transformed cells. Mol Cell Biol 1994; 14:851-8.
88. Salnikow K, Wang S, Costa M. Induction of activating transcription factor 1 by nickel and its role as a negative regulator of thrombospondin I gene expression. Cancer Res 1997; 57:5060-6.
89. Rubin H. Selected cell and selective microenvironment in neoplastic development. Cancer Res 2001; 61:799-807.
90. Stackpole CW, Groszek L, Kalbag SS. Benign-to-malignant B16 melanoma progression induced in two stages in vitro by exposure to hypoxia. J Natl Cancer Inst 1994; 86:361-7.
91. Mihaylova VT, Bindra RS, Yuan J, Campisi D, Narayanan L, Jensen R, et al. Decreased expression of the DNA mismatch repair gene Mlh1 under hypoxic stress in mammalian cells. Mol Cell Biol 2003; 23:3265-73.
92. Achison M, Hupp TR. Hypoxia attenuates the p53 response to cellular damage. Oncogene 2003; 22:3431-40.
93. Blagosklonny MV, An WG, Romanova LY, Trepel J, Fojo T, Neckers L. p53 inhibits hypoxia-inducible factor-stimulated transcription. J Biol Chem 1998; 273:11995-8.
94. Blagosklonny MV. Oncogenic resistance to growth-limiting conditions. Nat Rev Cancer 2002; 2:221-5.
95. Salnikow K, Costa M, Figg WD, Blagosklonny MV. Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer. Cancer Res 2000; 60:5630-4.
96. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379:88-91.
97. Maehle L, Metcalf RA, Ryberg D, Bennett WP, Harris CC, Haugen A. Altered p53 gene structure and expression in human epithelial cells after exposure to nickel. Cancer Res 1992; 52:218-21.
98. Lin X, Dowjat WK, Costa M. Nickel-induced transformation of human cells causes loss of the phosphorylation of the retinoblastoma protein. Cancer Res 1994; 54:2751-4.
99. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 2001; 276:9519-25.
100. Mazure NM, Chen EY, Yeh P, Laderoute KR, Giaccia AJ. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res 1996; 56:3436-40.
101. Haugen A, Ryberg D, Hansteen IL, Dalen H. Transformation of human kidney epithelial cells to tumorigenicity by nickel(II) and V-HA-RAS oncogene. Biol Trace Elem Res 1989; 21:451-8.